Exscientia initiates prospective observational study in ovarian cancer

Exscientia announced the initiation of EXCYTE-1, a prospective observational study in ovarian cancer to investigate the relationship between ex vivo drug response n primary tumour-derived samples using the company’s precision medicine platform and actual patient clinical response. This first of its kind observational study in solid tumours will run at multiple medical research centres in Europe with a focus on ovarian cancers. It aims to inform and enable future studies in other solid tumours. Ovarian cancer represents a high unmet need for predicting patient response to diverse therapy options. The study will be conducted in collaboration with the Arbeitsgemeinschaft Gynakologische Onkologie Study Group, one of the leading non-profit clinical research networks in gynaeco-oncology worldwide. “We are thrilled to work with Exscientia to advance the state of science and potential treatment of ovarian cancer patients,” said Professor Philipp Harter M.D., Ph.D., Head of Gynaecology and Gynaeco-Oncology at Evangelische Kliniken Essen-Mitte, Germany, and Chair of the AGO Study Group. “This study will enable us to explore new ways to identify the right treatment for individual patients, especially in cases with no available molecular biomarkers. We look forward to being a part of this important scientific evaluation.”